The Phase 3 success removes clinical risk for LUMRYZ in IH, but the 2028 marketing restriction caps near-term revenue upside. Watch for sNDA filing progress and FDA acceptance in H2 2026; any update on the settlement agreement timeline could be a catalyst. The stock may gap up on the clinical data but the delayed commercial launch limits the magnitude.
Price Chart
Executive Summary
Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia (IH), meeting all primary and key secondary endpoints with high statistical significance (p<0.0001). The company plans to file an sNDA with the FDA by end of 2026, but a prior settlement agreement bars marketing LUMRYZ for IH before March 1, 2028, even if approved. This is a clear clinical win that expands LUMRYZ's addressable market into a rare disease affecting ~40,000 U.S. patients, though commercial upside is delayed by the marketing restriction.
Key Facts
- LUMRYZ met the primary endpoint (ESS, p<0.0001) and all key secondary endpoints (PGI-C, IHSS, both p<0.0001) in the REVITALYZ Phase 3 study for idiopathic hypersomnia.
- Safety profile consistent with known LUMRYZ data; no new safety signals observed.
- Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026.
- A prior settlement and license agreement prohibits marketing LUMRYZ for IH before March 1, 2028, even if FDA approval is granted earlier.
- Idiopathic hypersomnia affects an estimated 40,000 people in the U.S., representing a new, addressable rare disease market for LUMRYZ.
Financial Impact
No financial figures provided in the filing. LUMRYZ is already approved for narcolepsy; IH label expansion opens a new market of ~40,000 U.S. patients, but commercialization is barred until March 1, 2028.
Risk Factors
- Marketing restriction until March 1, 2028 limits near-term revenue from IH even if FDA approves.
- FDA may not accept or approve the sNDA; regulatory risk remains.
- Competition from other IH treatments could emerge before 2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218150 |
| Document: alks-20260512.htm | 0001193125-26-218150 |
| Document: 0001193125-26-218150-index-headers.html | 0001193125-26-218150 |
| Document: 0001193125-26-218150-index.html | 0001193125-26-218150 |
| Document: 0001193125-26-218150.txt | 0001193125-26-218150 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $46.07 $42.13 | ▼ −8.55% | ▼ −11.12% | $41.75 (−9.38%) |
Sep 3, 2026 28d ago | Insider Cluster | $46.10 $45.83 | ▼ −0.59% | ▲ +0.62% | $41.75 (−9.44%) |
Aug 3, 2026 8w ago | Insider Cluster | $49.67 $49.21 | ▲ +0.93% | ▲ +0.83% | $41.75 (+15.95%) |
Aug 3, 2026 8w ago | Insider Cluster | $49.67 $49.21 | ▼ −0.93% | ▼ −0.83% | $41.75 (−15.95%) |
Aug 3, 2026 8w ago | Insider Cluster | $49.67 $49.21 | ▼ −0.93% | ▼ −0.83% | $41.75 (−15.95%) |
Jul 28, 2026 9w ago | 8-K | $50.50 $49.53 | ▲ +1.92% | ▲ +4.19% | $41.75 (+17.33%) |
Jul 8, 2026 12w ago | 8-K | $54.29 $51.60 | ▼ −4.95% | ▼ −5.82% | $41.75 (−23.10%) |
Jul 6, 2026 12w ago | Insider Cluster | $55.14 $51.94 | ▼ −5.80% | ▼ −6.29% | $41.75 (−24.28%) |
Jun 4, 2026 17w ago | Insider Cluster | $42.80 $44.28 | ▲ +3.46% | ▲ +2.89% | $41.75 (−2.45%) |
Jun 1, 2026 17w ago | Insider Cluster | $41.19 $44.29 | ▲ +7.53% | ▲ +10.50% | $41.75 (+1.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access